Jessica N. Abraham | Designer. Writer. Publicist.

19+ Years of Expertise in Digital Marketing, Social Branding and Public Relations.

  • Home
  • Contact
  • About
  • Home
  • Contact
  • About

No Widgets found in the Sidebar Alt!

  • What is ImQuest, and How is Statera Biopharma using it to Develop New Immune Therapies for Cancer, Infectious Disease and Autoimmune Disorders?
    Business,  Benzinga,  Biotechnology,  Finance,  Health

    What is ImQuest, and How is Statera Biopharma using it to Develop New Immune Therapies for Cancer, Infectious Disease and Autoimmune Disorders?

    September 8, 2021 /

    Previously Published to Benzinga: The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Statera Biopharma, Inc. (NASDAQ: STAB) — the company formerly known as Cytocom (NASDAQ: CBLI) — recently uplisted to the Nasdaq in lieu of earlier acquisitions involving Cleveland BioLabs and ImQuest Life Sciences, Inc. Last week, the company provided an update on its integration of ImQuest and its plans going forward.  According to Statera, preclinical testing is underway in the screening of second-generation immune therapies using the ImQuest platform for the rapid and accurate assessment of various diseases and how the overall makeup and composition of these diseases interact. The company will look more closely…

    read more
    Jessica N. Abraham Comments Off on What is ImQuest, and How is Statera Biopharma using it to Develop New Immune Therapies for Cancer, Infectious Disease and Autoimmune Disorders?

    You May Also Like

    Omni-Channel Customer Engagement, Omni-Channel, omnichannel, omni channel, customer engagement, self service, multichannel, mobile customer care

    The Difference Between Enterprise and Mid-Size Customer Service Solutions and Why Aspect is a Big Deal

    January 6, 2016
    Next Generation Communications, IP Transformation, Advanced Broadband Networks, Digital Lifestyles, Eco-Sustainable Telco Solutions, Dynamic Enterprise, Service Delivery Environment, Advanced Broadband Networks, End to End Transformation, Advanced Business Models, Business Transformation, Services Transformation, Service Delivery Platform, Killer Telco Environment and Managed Telco Services, Next Generation Communications, IP Transformation, Advanced Broadband Networks, Digital Lifestyles, Eco-Sustainable Telco Solutions, Dynamic Enterprise, Service Delivery Environment, Advanced Broadband Networks, End to End Transformation, Advanced Business Models, Business Transformation, Services Transformation, Service Delivery Platform, Killer Telco Environment and Managed Telco Services

    New York City Will Be America’s First Smart City

    January 11, 2016
    DISC Insights, DISC Personality, Personality Type, Corporate Culture, Employee Relations, Persona, Behavioral Analysis, Coaching, Dominance, Influence, Hiring Cycles, Recruitment, Talent Acquisition, Onboarding, Team Building, Leadership, Workforce Optimization, Corporate Development, Business Development, Business Expansion, Growth, Team Building, Culture, Building Remote Teams, Compliances, Roles, Infrastructure, Differences in Opinion,

    Managing remote teams with DISC

    July 13, 2019
  • Statera Biopharmaceuticals, Groundbreaking Biomedicine Treatment
    Health,  Benzinga,  Biotechnology,  Business,  Finance

    Statera BioPharma: The Ticker Formerly Known as CBLI

    September 7, 2021 /

    Previously Published to Benzinga: The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. On September 1, 2021, Cytocom officially became listed as Statera BioPharma, Inc. (NASDAQ: STAB), as it updated its ticker symbol from CLBI to STAB within the Nasdaq markets.  This change in name comes as a natural progression, as the company shifts gears toward placing a more strategic focus on restoring total immune health — including autoimmune and inflammatory diseases, such as fibromyalgia and multiple sclerosis, blood disorders like anemia and lupus, even cancer and various other infectious diseases.  The company began trading as CLBI, last month,…

    read more
    Jessica N. Abraham Comments Off on Statera BioPharma: The Ticker Formerly Known as CBLI

    You May Also Like

    Top Tech Startups, Best Tech Startups, Denver Colorado

    BEST TECH STARTUPS IN DENVER, RANKED

    May 20, 2021
    Technical advancements in stem cell therapies have reportedly shifted the outlook of regenerative medicine, and some scientists are getting increasingly excited. Cardiologist Dr. Joshua Hare is one of those scientists, and he’s both the co-founder and chief scientific officer of Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions. He’s also credited with helping to pioneer the use of stem cells as medicine for the human heart and regularly explores a future where regenerative medicine can prolong human life.

    Should Aging Be Treated As A Disease? And How One Company Might Be Shifting The Paradigm To Reverse It

    June 15, 2022
    Goats, Animal Bedding, anti-pest, anti-mold, anti-bacterial, industrial hemp industry,

    Research Shows that Animals, too, Need a Good Night’s Sleep

    September 14, 2021
  • Business
  • Technology
  • Career Development
  • Education
  • Entertainment
  • Fashion
  • Relationships
  • Tips
  • Travel
Ashe Theme by WP Royal.